Immunoglobulin G1 [300-Alanine], Anti-(Human Cd73 Antigen) (Human-Mus Musculus Monoclonal Tj004309 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Tj004309 ?-Chain, Dimer
Ovarian Carcinoma
Explore 236 assets in Ovarian Carcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
I-Mab Biopharma US Limited
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05001347CT.gov A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [300-Alanine], Anti-(Human Cd73 Antigen) (Human-Mus Musculus Monoclonal Tj004309 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Tj004309 ?-Chain, Dimer (this asset) | I-Mab Biopharma US Limited | P2 | B · 57 |
| Mirvetuximab Soravtansine | AstraZeneca | P3 | BBB |
| Trabectedin | AGO Research GmbH | P4 | BBB |
| Carboplatin | University of Washington | P3 | BB |
| Olaparib | Imunon | P4 | BB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Durvalumab | AGO Research GmbH | P2 | BB |
+42 more in the Ovarian Carcinoma cohort
Other indications for Immunoglobulin G1 [300-Alanine], Anti-(Human Cd73 Antigen) (Human-Mus Musculus Monoclonal Tj004309 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Tj004309 ?-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Cancer | — | P2 | B · 57 |
| Head And Neck Cancer | — | P2 | CCC · 54 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [300-Alanine], Anti-(Human Cd73 Antigen) (Human-Mus Musculus Monoclonal Tj004309 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Tj004309 ?-Chain, Dimer in Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-300-alanine-anti-human-cd73-antigen-human-mus-musculus-monoclonal-tj004309-1-chain-disulfide-with-human-mus-musculus-monoclonal-tj004309-chain-dimer-ovarian-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →